IN VIVO PROTON MRS DETECTION OF MALIGNANT BREAST CANCER

长期目标是研究和开发体内质子 磁共振波谱（MRS）用于早期诊断和管理 乳腺癌短期目标是开发一种光谱成像 方法Sel-MQC（选择性多量子相干转移），其允许 代谢物和不饱和脂肪酸的非侵入性质子检测 具有临床可接受的时间效率和空间分辨率的乳腺组织。 对来自脂质和水的强信号的鲁棒抑制将是有效的。 在一次扫描中完成。代谢物和脂质分子将 随后作为分子标记物进行研究，以区分良性和 人类乳腺恶性肿瘤我们在资助期内的目标是：（1） 在低场2.1T人体MRI/MRS上开发和实施Sel-MQC方法 光谱仪无论是低强度商用磁场梯度还是强 将采用专门构建的局部磁场梯度 有效的相干性选择和过滤。将制定方案， 乳腺癌中乳酸、胆碱和不饱和脂质分子的检测 患者(2)为了使用Sel-MQC序列开发多切片模块， 提高代谢监测空间分辨率的Hadmard矩阵方法 人类乳腺癌的变化。 该项目将扩展体内质子MRS，超越目前的检查限制 脑内的代谢物肿瘤特异性分子的检测和 浸润前乳腺良恶性病变的鉴别 （可能在任何形态学变化之前）通过质子MRS将改善 乳腺癌治疗的效率和乳腺癌的成本效益 在乎所提出的方法将在其他机构中得到更广泛的应用。

The long-term goal is to investigate and develop in vivo proton magnetic resonance spectroscopy (MRS) for early diagnosis and management of breast cancer. The short-term objective is to develop a spectroscopic imaging method Sel-MQC (Selective Multiple-Quantum Coherence transfer) that permits non-invasive proton detection of metabolites and unsaturated fatty acids in breast tissue with clinical acceptable time efficiency and spatial resolution. Robust suppression of the intensive signals from lipid and water will be achieved in a single scan. The metabolite and lipid molecules will be subsequently investigated as molecular markers to differentiate benign and malignant human breast tumors. Our aims in this grant period are: (1) To develop and implement the Sel-MQC methods on a low field 2.1T human MRI/MRS spectrometer. Both low-strength commercial magnetic field gradients or strong specifically built local magnetic field gradients will be employed for efficient coherence selection and filtering. Protocols will be established for detection of lactate, choline, and unsaturated lipid molecules in breast cancer patients. (2) To develop multi-slice modules of the Sel-MQC sequences using Hadmard matrix approach to improve spatial resolution in monitoring metabolic changes in human breast cancer. The project will extend in vivo proton MRS beyond current limit of examining metabolites inside brain. Detection of tumor-specific molecules and differentiation of malignant and benign breast lesions in pre-invasive stage (possibly before any morphological changes) by proton MRS will improve the efficiency of breast cancer therapy and the cost-effectiveness of breast cancer care. The proposed method will have wider applications in other organs.